The Burden of Vaccine-Preventable Diseases

The Vaccine Book

Volumn , Issue , 2003, Pages 1-21

  Birmingham, Maureen ^a   Stein, Claudia ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70249089870     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50003-2     Document Type: Chapter

References (124)

1. Murray C.J.L., Lopez A.D. Global Burden of Disease and Injury Series, Volume I. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 1996, Harvard University Press, Cambridge.
2. World Health Organization "The World Health Report 2001. Mental Health: New Understanding, New Hope" Geneva, Switzerland 2001.
3. The Buddhist Tradition in India, China and Japan 1972, Vintage Books, New York. W.T. DeBary (Ed.).
4. Plotkin S.L., Plotkin S.A. A short history of vaccination. Vaccines 1999, 1-12. Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
5. Pasteur L. Méthode pour prévenir la rage après morsure. C.R. Acad. Sci. Paris 1885, 101:765-772.
6. Salmon D.E. The theory of immunity from contagious diseases. Proc. Am. Assoc. Adv. Sci. 1886, 35:262-266.
7. Salmon D.E., Smith T. On a new method of producing immunity from contagious diseases. Am. Vet. Rev. 1886, 10:63-69.
8. Ramon G. Sur le pouvoir floculant et sur les propriétés immunisantes d'une toxine diphtérique rendue anatoxiquie (anatoxine). C.R. Acad. Sci. Paris 1923, 177:1338-1340.
9. Ramon G., Zoeller C. De la valeur antigénique de l'anatoxine tétanique chez l'homme. C.R. Acad. Sci. Paris 1926, 182:245-247.
10. Ramon G., Zoeller C. L'anatoxine tétanique et l'immunisation active de l'homme vis-à-vis du tétanos. Ann. Inst. Pasteur Paris 1927, 41:803-833.
11. Parish H.J. A History of Immunization 1965, E & S Livingstone, London.
12. Madsen T. Vaccination against whooping cough. J. Am. Med. Assoc. 1933, 101:187-188.
13. Edwards K.M., Decker M.D., Mortimer E.A. Pertussis vaccine. Vaccines 1999, 293-344. Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
14. Robbins F.C., Daniel T.M. A history of poliomyelitis. Polio 1997, 5-22. University of Rochester Press, Rochester, NY. T.M. Daniel, F.C. Robbins (Eds.).
15. Henderson D.A., Moss B. Smallpox and Vaccinia. Vaccines 1999, 74-97. Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
16. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. The intensified smallpox eradication programme, 1967-1980. Smallpox and Its Eradication 1988, 421-538. World Health Organization, Geneva, Switzerland.
17. Henderson R.H., Keja K., Galazka A.M., Chan C.A. Reaping the benefits: Getting vaccines to those who need them. New Generation Vaccines 1990, 69-82. Marcel Dekker, New York. G.C. Woodrow, M.M. Levine (Eds.).
18. Redd S.C., Markowitz L.E., Katz S.L. Measles vaccine. Vaccines 1999, 222-266. Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
19. Thomas M.G. Epidemiology of pertussis. Rev. Infect. Dis. 1989, 11:255-262.
20. World Health Organization Progress toward the 1995 measles control goals and implications for the future. GPV/SAGE. 96WP.04 1996.
21. Lee J.W., Aylward B.R., Hull H.F., Batson A., Birmingham M.E., Lloyd J. Reaping the benefits: Getting vaccines to those who need them. New Generation Vaccines 1997, 79-88. Marcel Dekker, New York. G.C. Woodrow, M.M. Levine (Eds.).
22. World Health Organization Expanded Programme on Immunization. Weekly Epidemiol. Record 1977, 7:74-75.
23. Henderson R.H. Providing immunization: The state of the art. Protecting the World's Children: Vaccine and Immunization within Primary Health Care. Proceedings of the Bellagio Conference 1984, 17-37. The Rockefeller Foundation, New York.
24. World Health Organization WHA resolution 30.53. WHO Official Records 1977, 240(33):140.
25. Henderson R.H., Sundaresan T. Cluster sampling to assess immunization coverage: A review of experience with a simplified sampling method. Bull WHO 1982, 60:253-260.
26. Bernier R.H. Some observations on poliomyelitis lameness surveys. Rev. Infect. Dis. 1984, 6(Suppl. 2):S371-S375.
27. Stanfield J.P., Galazka A. Neonatal tetanus in the world today. Bull. WHO 1984, 62(4):647-669.
28. Galazka A., Stroh G. Neonatal tetanus. Guidelines on the community-based survey on neonatal tetanus mortality. WHO/EPI/GEN/86/8 1986.
29. Galazka A., Gasse F., Henderson R.H. Neonatal tetanus in the world and the global Expanded Programme on Immunization. 8th International Conference on Tetanus 1989, 470-487. Pythagora Press, Rome-Milan. G. Nistico, B. Bizzini, B. Bytchenko, R. Triau (Eds.).
30. LaForce F.M., Lichnevski M.S., Keja J., Henderson R.H. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries. Bull. WHO 1980, 58:609-620.
31. Grant J.P. The State of the World's Children in 1991 1991, Oxford University Press, Oxford, England.
32. World Health Organization Resolution WHA 41.28. Handbook of Resolutions and Decisions of the World Health Assembly and the Executive Board (1985-1992) 1993, Vol. III:100-101. World Health Organization, Geneva, Switzerland. 3rd ed.
33. World Health Organization Global Polio Eradication Progress 2000. WHO/polio/01.03 2001.
34. Murray C.J.L., Lopez A.D. Global Burden of Disease and Injury Series, Volume II. Global Health Statistics. A Compendium of Incidence, Prevalence and Mortality Estimates for over 200 Conditions 1996, Harvard University Press, Cambridge.
35. World Health Organization Global polio eradication initiative strategic plan 2001-2005. WHO/polio/00.05 2000.
36. Tangermann R.H., Hull H.F., Jafari H., Nkowane B., Everts H., Aylward R.B. Eradication of poliomyelitis in countries affected by conflict. Bull. WHO 2000, 78(3):330-338.
37. Sutter R.W., Tangermann R.H., Aylward R.B., Cochi S.L. Poliomyelitis eradication: Progress challenges for the end game, and preparation for the posteradication era. Infect. Dis. Clinics North America 2001, 15(1):41-64.
38. Melgaard B., Creese A., Aylward B., Olive J.M., Maher C., Okwo-Bele J.M., Lee J.W. Disease eradication and health systems development. Bull. WHO 1998, 76(Suppl. 2):26-31.
39. World Health Organization Resolution WHA 42.32. Handbook of Resolutions and Decisions of the World Health Assembly and the Executive Board (1985-1992) 1993, Vol. III:102. World Health Organization, Geneva, Switzerland. 3rd ed.
40. Grant J.P. First call for children. World Declaration and Plan of Action from the WSC, Convention on the Rights of the Child 1990, UNICEF, New York.
41. Hull H. Increased measles mortality in households with multiple cases in the Gambia, 1981. Rev. Infect. Dis. 1988, 10:463-467.
42. Markowitz L.E., Nzilambi N., Driskell W.J., Sension M.G., Rovira E.Z., Nieburg P., Ryder R.W. Vitamin A levels and mortality among hospitalised measles patients, Kinshasa, Zaire. J. Tropical Pediatr. 1989, 35:109-112.
43. Aaby P., Leeuwenburg J. Patterns of transmission and severity of measles infection: A reanalysis of data from the Machakos Area, Kenya. J. Infect. Dis. 1990, 161:171-174.
44. Sutter R.W., Markowitz L.E., Bennetch J.M., Morris W., Zell E.R., Preblud S.R. Measles among the Amish: A comparative study of measles severity in primary and secondary cases in households. J. Infect. Dis. 1991, 163:12-16.
45. Markowitz L.E., Nieberg P. The burden of acute respiratory tract infection due to measles in developing countries and the potential impact of measles vaccine. Rev. Infect. Dis. 1991, 13(Suppl. 6):S555-S561.
46. Aaby P. Introduction of community studies of severe measles: Comparative test of crowding/exposure hypothesis. Rev. Infect. Dis. 1988, 10:451.
47. Narain J.P., Khare S., Rana S.R., Banerjee K.B. Epidemic measles in an isolated unvaccinated population, India. Int. J. Epidemiol. 1989, 18:952-958.
48. World Health Organization High measles case-fatality rates during an outbreak in a rural area (Niger). Weekly Epidemiol. Record 1993, 68:142-145.
49. Agocs M.M., Markowitz L.E., Straub I., Domok I. The 1988-1990 measles epidemic in Hungary: Assessment of vaccine failure. Int. J. Epidemiol. 1992, 21:1007-1013.
50. Kambarami R.A., Nathoo K.J., Nkrumah F.K., Pirie D.J. Measles epidemic in Harare, Zimbabwe, despite high measles immunization coverage rates. Bull. WHO 1991, 69:213-219.
51. Chen R.T., Weierbach R., Bisoffi Z., Cutts F., Rhodes P., Ramaroson S., Htembagara C., Bizimana F. A "post-honeymoon period" measles outbreak in Muyinga sector, Burundi. Int. J. Epidmiol. 1994, 23:185-193.
52. McLean A.R., Anderson R.M. Measles in developing countries. Part II. The predicted impact of mass vaccination. Epidmiol. Infect. 1988, 100:419-442.
53. World Health Organization Vaccine-Preventable Disease Monitoring System. 2001 Global Summary. WHO/V&B/01.34 2001.
54. de Quadros C.A., Olive J.M., Hersh B.S., Strassburg M.A., Henderson D.A., Brandling-Bennett D., Alleyne G.A.O. Measles elimination in the Americas: Evolving strategies. J. Am. Med. Assoc. 1996, 275:224-229.
55. Centers for Disease Control and Prevention Measles eradication: Recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. Morb. Mortal. Wkly. Rep. 1997, 46:1-20. RR11.
56. World Health Organization Progress toward interrupting indigenous measles transmission in the western hemisphere. Weekly Epidemiol. Record 2000, 75(40):354-358.
57. World Health Organization Expanded Programme on Immunization. Rubella and congenital syndrome in the Americas. Weekly Epidemiol. Record 1997, 72(40):301-303.
58. World Health Organization Accelerated rubella and congenital rubella syndrome programme, Costa Rica. Weekly Epidemiol. Record 2001, 76:265-270. 35.
59. World Health Organization Preventing congenital rubbel syndrome. Weekly Epidemiol. Record 2000, 75(36):290-295.
60. Wakefield A.J. MMR vaccination and autism. Lancet 1999, 354(9182):949-950.
61. Wakefield A.J., Murch S.H., Anthony A., Linnell J., Casson D.M., Malik M., Berelowitz M., Dhillon A.P., Thomson M.A., Harvey P., Valentine A., Davies S.E., Walker-Smith J.A. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998, 351(9103):637-641.
62. World Health Organization Expanded Programme on Immunization (EPI). Association between measles infection and the occurrence of chronic inflammatory bowel disease. Weekly Epidemiol. Record 1998, 73(6):33-39.
63. Peltola H., Patja A., Leinikki P., Valle M., Davidkin I., Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998, 351(9112):1327-1328.
64. DeStefano F., Chen R.T. Autism and measles, mumps, and rubella vaccine: No epidemiological evidence for a causal association. J. Pediatr. 2000, 136(1):125-126.
65. Halsey N.A., Hyman S.L., Conference Writing Panel Measles-mumps-rubella vaccine and autistic spectrum disorder: Report from the New Challenges in Childhood Immunizations Conference convened. Pediatrics 2001, 107:E84. 5.
66. Kastner J.L., Gellin B.G. Measles-mumps-rubella vaccine and autism: The rise (and fall?) of a hypothesis. Pediatr. Ann. 2001, 30(7):408-415.
67. Kaye J.A., Maria Del Mar M.M., Jick H. Mumps, measles, and rubella vaccine and the incidence of austism recorded by general practitioners: A time-trend analysis. West. J. Med. 2001, 174(6):387-390.
68. Anonymous Fall in MMR vaccine coverage reported as further evidence of vaccine safety is published. Commun. Dis. Rep. Wkly. 1999, 9(26):227.
69. Anonymous Fall in MMR vaccine coverage reported as further evidence of vaccine safety is published. Commun. Dis. Rep. Wkly. 1999, 9(26):230.
70. World Health Organization Measles mortality reduction and regional elimination strategic plan, 2001-2005. WHO/V&B/01.13 2001.
71. UNICEF, WHO, UNFPA Maternal and neonatal tetanus elimination by 2005. Strategies for Achieving and Maintaining Elimination 2000, UNICEF, New York.
72. Fauveau V., Mamdani M., Steinglass R., Koblinsky M. Maternal tetanus: Magnitude, epidemiology and potential control measures. Int. J. Gynecol. Obstet. 1993, 40:3-12.
73. Centers for Disease Control and Prevention Tetanus-United States, 1982-1984. Morb. Mort. Wkly. Rep. 1985, 34(39):602-611.
74. Crossley K., Irvine P., Warren B., Lee B., Mead K. Tetanus and diphtheria immunity in urban Minnesota adults. J. Am. Med. Assoc. 1979, 242:2298-2300.
75. Simonsen O., Block A.V., Klaerke A., Klaerke M., Kjeldsen K., Heron I. Immunity against tetanus and response to revaccination in surgical patients more than 50 years of age. Surg. Gynecol. Obstet. 1987, 164:329-334.
76. Kjeldsen K., Simonsen O., Heron I. Immunity against diphtheria and tetanus in the age group 30-70 yrs. Scand. J. Infect. Dis. 1988, 20:177-185.
77. World Health Organization Eliminating neonatal tetanus. How near, how far?. WHO/EPI/GEN/96.01 1996.
78. Mortimer E.A., Wharton M. Diphtheria toxoid. Vaccines 1997, 1-12. Saunders, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
79. English P.C. Diphtheria and theories of infectious disease: Centennial appreciation of the critical role of diphtheria in the history of medicine. Pediatrics 1985, 76:1-9.
80. Doull J.A. The bacteriological era (1876-1920). The History of American Epidemiology 1952, 74-103. Mosby Co., St Louis. F.H. Top (Ed.).
81. Kass A.M. Infectious diseases at the Boston City Hospital: The first 60 years. Clin. Infect. Dis. 1993, 17:276-282.
82. Kostrzewski J. Blonica (diphtheria). "Infectious Diseases in Poland and Their Control in 1919-1962" (in Polish) 1964, 96-117. Panstwowy Zaklad Wydawnictw Lekarskich, Warsaw, Poland.
83. McKinnon N.E. Diphtheria prevented. Control of the Common Fevers 1942, 41-52. The Lancet Ltd., London. R. Cruickshank (Ed.).
84. Galazka A.M., Robertson S.E., Oblapenko G.P. Resurgence of diphetheria. Eur. J. Epidemiol. 1995, 11(1):95-105.
85. Stowman K. Diphtheria rebounds. Epidemiol. Inf. Bull. 1945, 1:157-168. United Nations Relief and Rehabilitation Administration.
86. Stuart G. A note on diphtheria incidence in certain countries. Br. Med. J. 1945, 2:613-615.
87. Wheeler S.M., Morton A.R. Epidemiological observations in the Halifax epidemic. Am. J. Public Health 1942, 32:942-956.
88. Fleck S., Kellam J.W., Klippen A.J. Diphtheria among German prisoners of war. Bull. U.S. Army Med. Dept. 1944, 74:80-89.
89. Galazka A.M., Robertson S.E. Diphtheria-changing patterns in the developing world and the industrialized world. Eur. J. Epidemiol. 1995, 11(1):107-117.
90. World Health Organization Expanded Programme on Immunization. Diphtheria control. Weekly Epidemiol. Record 1997, 72(18):128-130.
91. Galazka A. Control of pertussis in the world. World Health Stat. Q. 1992, 45:238-247.
92. Wright P.F. Pertussis in developing countries. Definition of the problem and prospects for control. Rev. Infect. Dis. 1991, 13(Suppl.):S528-S534.
93. Center for Disease Control and Prevention Pertussis surveillance-United States, 1986-1988. Morb. Mortal. Wkly. Rep. 1990, 39:57-66.
94. Clarkson J.A., Fine P.E.M. The efficacy of measles and pertussis notification in England and Wales. Int. J. Epidemiol. 1985, 14:153-168.
95. Sutter R.W., Cochi S.L. Pertussis hospitalizations and mortality in the United States, 1985-1988. J. Am. Med. Assoc. 1992, 267(3):386-391.
96. Halperin S.A., Bortolussi R., Maclean D., Chisholm N. Persistance of pertussis in an immunized population: Results of the Nova Scotia enhanced pertussis surveillance programme. J. Pediatr. 1989, 115:686-693.
97. Cherry J.P., Brunell P.A., Golden G.S., Karzon D.T. Report of the task force on pertussis and pertussis immunization. Pediatr. Suppl. 1988, 81(6):939-984. Part 2.
98. Onorato I.M., Wassilak S.G.F. Laboratory diagnosis of pertussis: The state of art. Pediatr. Infect. Dis. J. 1987, 6:145-151.
99. Gangarosa E.J., Galazka A.M., Wolfe C.R., Phillips L.M., Gangarosa R.E., Miller E., Chen R.T. Impact of anti-vaccine movements on pertussis control: The untold story. Lancet 1998, 351(9099):356-361.
100. World Health Organization Pertussis vaccines. WHO position paper. Weekly Epidemiol. Record 1999, 74(18):137-143.
101. World Health Organization Pertussis surveillance. A global meeting. WHO/V&B/01.19 2001.
102. World Health Organization Sustainable outreach services (SOS). A strategy for reaching the unreached with immunization and other services. WHO/V&B/00.37 2000.
103. Salmon D.A., Haber M., Gangarosa E.J., Phillips L., Smith N.J., Chen R.T. Health consequences of religious and philosophical exemptions from laws: Individual and societal risk of measles. J. Am. Med. Assoc. 1999, 282(1):47-53.
104. World Health Organization Expanded Programme on Immunization. Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Weekly Epidemiol. Record 1997, 72(21):149-153.
105. World Health Organization Global Programme for Vaccines and Immunization (GPV). The WHO position paper on Haemophilus influenzae type B conjugate vaccines. Weekly Epidemiol. Record 1998, 73(10):64-68.
106. World Health Organization Pneumococcal vaccines. WHO position paper. Weekly Epidemiol. Record 1999, 74(23):177-183.
107. World Health Organization Typhoid vaccines. WHO position paper. Weekly Epidemiol. Record 2000, 75(32):257-264.
108. World Health Organization Expanded Programme on Immunization. Weekly Epidemiol. Record 1997, 72(6):36-40.
109. World Health Organization Vaccine research and development. New strategies for accelerating Shigella vaccine development. Weekly Epidemiol. Record 1997, 72(11):73-79.
110. World Health Organization New frontiers in the development of vaccines against enteroxigenic (ETEC) and enterohemorrhagic (EHEC) E. coli. Weekly Epidemiol. Record 1999, 74(13):98-101.
111. World Health Organization Group A and C meningococcal vaccines. WHO position paper. Weekly Epidemiol. Record 1999, 74(36):297-303.
112. World Health Organization The current status of development of prophylactic vaccines against human papilloma virus infections. WHO/V&B/99.04 1999.
113. World Health Organization Proceedings of the first global vaccine research forum. WHO/V&B/01.21 2001.
114. World Health Organization Cholera vaccines. WHO position paper. Weekly Epidemiol. Record 2001, 76(16):117-124.
115. World Health Organization Chiangmai declaration on dengue/dengue hemorrhagic fever. Strengthening efforts to control dengue in the new millenium. Weekly Epidemiol. Record 2001, 76(4):29-30.
116. Global Alliance for Vaccines and Immunization Meeting of the Proto Board. GAVI/99.01 1999.
117. Collins C. Sustaining support for domestic HIV vaccine research: Social issues over the long haul of human trials. Occasional Paper No. 2 1996, Center for AIDS Prevention Studies (CAPS), Atlanta.
118. Malaria Vaccine Initiative 2001, http://www.malariavaccine.org.
119. World Health Organization WHO Report 2001-Global Tuberculosis Control. WHO/CDS/TB/2001.287 2001.
120. Rodrigues L.C., Smith P.G. Tuberculosis in developing countries and methods for its control. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:739-744.
121. World Health Organization Issues relating to the use of BCG in immunization programmes-A discussion document. WHO/V&B/99.23 1999.
122. Styblo K., Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976, 57(1):17-43.
123. Ponnighaus J.M., Fine P.E., Sterne J.A., Wilson R.J., Msosa E., Gruer P.J., Jenkins P.A., Lucas S.B., Liomba N.G., Bliss L. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992, 339:636-639.
124. Orme I.M. Progress in the development of new vaccines against tuberculosis. Int. J. Tuberc. Lung Dis. 1997, 1(2):95-100.